利妥昔单抗与环孢素治疗膜性肾病的成本效果分析:MENTOR试验经济学评价
生物类似药降低成本可进一步改善成本效果,部分情景下利妥昔单抗成为优势方案。
要点
- 利妥昔单抗治疗膜性肾病相比环孢素具成本效果,ICER为8373美元/QALY。
- 低成本生物类似药可改善成本效果,部分情景下达优势。
核心结论
- 尽管利妥昔单抗成本更高,但相比环孢素治疗膜性肾病可能具有成本效果。
- 使用更廉价的生物类似药可进一步改善利妥昔单抗的成本效果。
研究设计与样本
- 采用Markov模型,从医疗支付方角度、终身时间跨度评估利妥昔单抗对比环孢素的增量成本效果比(ICER)。
- 模型参数尽可能基于MENTOR试验数据,成本和效用输入来自文献。
主要发现
- 利妥昔单抗生物类似药成本降低导致更有利的ICER,部分情况下利妥昔单抗成为优势方案(成本更低且获益更大)。
临床怎么用
- 优先使用低成本生物类似药可进一步改善成本效果,部分情景下利妥昔单抗成为优势方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: The MENTOR trial (MEmbranous Nephropathy Trial Of Rituximab) showed that rituximab was noninferior to cyclosporine in inducing complete or partial remission of proteinuria and was superior in maintaining proteinuria remission. However, the cost of rituximab may prohibit first-line use for some patients and health-care payers. METHODS: A Markov model was used to determine the incremental cost-effectiveness ratio (ICER) of rituximab compared with cyclosporine for the treatment membranous nephropathy from the perspective of a health-care payer with a lifetime time horizon. The model was informed by data from the MENTOR trial where possible; additional parameters including cost and utility inputs were obtained from the literature. Sensitivity analyses were performed to evaluate the impact of reduced-cost biosimilar rituximab. RESULTS: Rituximab for the treatment of membranous nephropathy was cost effective (assuming a willingness-to-pay threshold of $50 000 per quality-adjusted life year (QALY) gained; in $US 2021) compared with cyclosporine, with an ICER of $8373/QALY over a lifetime time horizon. The incremental cost of rituximab therapy was $28 007 with an additional 3.34 QALYs compared with cyclosporine. Lower cost of rituximab biosimilars resulted in a more favorable ICER, and in some cases resulted in rituximab being dominant (lower cost and great benefit) compared to cyclosporine. CONCLUSIONS: Despite the greater cost of rituximab, it may be a cost-effective option for the treatment of membranous nephropathy when compared with cyclosporine. The cost-effectiveness of rituximab is further improved with the use of less expensive biosimilars.
引用
- Kadatz M, Klarenbach S, So H, et al. Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial. Nephrol Dial Transplant. 2024. PMID: 38621719. doi:10.1093/ndt/gfae084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。